Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study

Journal of Molecular Modeling

Volumn 21, Issue 2, 2015, Pages 1-12

  Yang, Bei ^a   Zhang, Haiping ^a   Wang, Hao ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Drug resistance; HER2; Lung cancer; MD simulation; MM GBSA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCINE; LAPATINIB; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CLUSTER ANALYSIS; ENERGY; GENE MUTATION; LUNG CANCER; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PRIORITY JOURNAL; ALLELE; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG RESISTANCE; GENETICS; HUMAN; LUNG TUMOR; MUTATION;

ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84921819967     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-015-2580-x     Document Type: Article

References (51)

1. Schlessinger J, Lemmon MA (2006) Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127:45–48
2. Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74
3. Tao R-H, Maruyama IN (2008) All EGF(ErbB) receptors have performed homo- and heterodimeric structures in living cells. J Cell Sci 121:3207–3217
4. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, Ferguson KM (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25:7734–7742
5. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31
6. Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312:1175–1178
7. Oqiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775–787
8. Oxnard GR, Miller VA (2010) Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology 24:392–399
9. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht R, Slamon DJ, Finn RS (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cell and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509–1519
10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paguette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880
11. Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10–18
12. Avizienyte E, Ward RA, Garner AP (2008) Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 145:197–206
13. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase domain causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070–2075
14. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14:7519–7525
15. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER (2008) Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68:571–579
16. Trowe T, Boukouvala S, Calkins K, Cutler RE, Ryan Fong C Jr, Funke R, Gendreau SB, Kin YD, Miller N, Woodlfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS (2008) EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14:2465–2475
17. Stephens P, Hunter C, Biqnell G, Edkins S, Davies H, Teaque J, Stevens C, O’Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stenphens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Woodster R, Stratton MR (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431:525–526
18. Aertgeerts K, Skene R, Yano J, Sang B-C, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 186:18756–18765
19. Fiser A, Do RK, Sali A (2000) Modeling loops in protein structures. Protein Sci 9:1753–1773
20. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA (2003) Guassian 03. Gaussian, Inc., Wallingford
21. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791
22. Lu S, Huang W, Li X, Huang Z, Liu X, Chen Y, Shi T, Zhang J (2012) Insights into the role of magnesium traid in myo-inositol monophosphatase: metal mechanism, substrate binding, and lithium therapy. J Chem Inf Model 52:2398–2409
23. Lu S, Huang W, Wang Q, Shen Q, Li S, Nussinov R, Zhang J (2014) The structural basis of ATP as an allosteric modulator. PLoS Comput Biol 10:e1003831
24. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts BP, Wang B, Hayik S, Roitberg A, Seabra G, Kolossvary I, Wong KF, Paesani F, Vanicek J, Liu J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh MJ, Cui G, Roe DR, Mathews DH, Seetin MG, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman PA (2010) AMBER 11. University of California, San Francisco
25. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T (2003) A point-charge force field for molecular mechanics simulations of proteins. J Comput Chem 24:1999–2012
26. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174
27. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of single potential function for simulating liquid water. J Chem Phys 79:926–935
28. Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092
29. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327–341
30. Wu X, Brooks BR (2003) Self-guided Langevin dynamics simulation method. Chem Phys Lett 381:512–518
31. Huang Y, Rizzo RC (2012) A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases. Biochemistry 51:2390–2406
32. Ahmed M, Sadek MM, Abouzid KA, Wang F (2013) In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. J Mol Graph Model 44:220–231
33. Sun H, Li Y, Tian S, Xu L, Hou T (2014) Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys 16:16719–16729
34. Bai Q, Pérez-Sánchez H, Zhang Y, Shao Y, Shi D, Liu H, Yao Y (2014) Ligand induced change of β2 adrenergic receptor from active to inactive conformation and its implication for the closed/open state of the water channel: insight from molecular dynamics simulation, free energy calculation and Markov state model analysis. Phys Chem Chem Phys 16:15874–15885
35. Shao J, Tanner SW, Thompson N, Cheatham TEIII (2007) Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J Chem Theory Comput 3:2312–2334
36. Luo J, Bruice T (2002) Ten-nanosecond molecular dynamics simulation of the motions of the horse liver alcohol dehydrogenase•PhCH2O- complex. Proc Natl Acad Sci USA 99:16597–16600
37. Li X, Wang X, Tian Z, Zhao H, Liang D, Li W, Qiu Y, Lu S (2014) Structural basis of valmerins as dual inhibitors of GSK3β/CDK5. J Mol Model 20:2407
38. Palmieri L, Rastelli G (2013) αC helix displacement as a general approach for allosteric modulator of protein kinases. Drug Discov Today 18:407–414
39. Lu S, Li S, Zhang J (2014) Harnessing allostery: a novel approach to drug discovery. Med Res Rev 34:1242–1285
40. Adams JA (2003) Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? Biochemistry 42:601–607
41. Nolen B, Taylor S, Ghosh G (2004) Regulation of protein kinases. Mol Cell 15:661–675
42. Lu S, Jiang Y, Lv J, Zou J, Wu T (2011) Mechanism of kinase inactivation and nonbinding of FRATide to GSK3β due to K85M mutation: molecular dynamics simulation and normal mode analysis. Biopolymers 95:669–681
43. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9:167–181
44. Kumar R, Chaudhary K, Gupta S, Singh H, Kumar S, Gautam A, Kapoor P, Raghava GPS (2014) CancerDR: cancer drug resistance database. Sci Rep 3:1445
45. Sun H, Li Y, Tian S, Wang J, Hou T (2014) P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. PLoS Comput Biol 10:e1003729
46. Shao S, Yu R, Yu Y, Li Y (2014) Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. J Mol Model 20:2399
47. Lu S, Huang W, Zhang J (2014) Recent computational advances in the identification of allosteric sites in proteins. Drug Discov Today 19:1595–1600
48. Li J, Rossetti G, Dreyer J, Raugei S, Ippolitti E, Lüscher B, Carloni P (2014) Molecular simulation-based structural prediction of protein complexes in mass spectrometry: the human insulin dimer. PLoS Comput Biol 10:e1003838
49. Chebaro Y, Amal I, Rochel N, Rochette-Egly C, Stote RH, Dejaegere A (2013) Phosphorylation of the retinoic acid receptor alpha induces a mechanical allosteric regulation and changes in internal dynamics. PLoS Comput Biol 9:e1003012
50. Koch O, Cappel D, Nocker M, Jäger T, Flohé L, Sotriffer CA, Selzer PM (2013) Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS One 8:e56788
51. Onufriev A, Bashford D, Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized Born model. Proteins 55:383–394